---
title: "Tinlarebant (LBS-008) in Stargardt disease type 1: Terms and abbreviations"
description: "Formulary evidence on Tinlarebant (LBS-008) in Stargardt disease type 1: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/terms-and-abbreviations"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tinlarebant (LBS-008) in Stargardt disease type 1: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| ABCA4 | ATP-binding cassette subfamily A member 4 |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| AUCinf | Area under the concentration-time curve extrapolated to infinity |
| BCVA | Best-corrected visual acuity |
| BD | Twice daily |
| CI | Confidence interval |
| Cmax | Maximum plasma concentration |
| CYP3A | Cytochrome P450 3A |
| DAF | Decreased autofluorescence |
| DDAF | Definitely decreased autofluorescence |
| DNA | Deoxyribonucleic acid |
| FAF | Fundus autofluorescence |
| FDA | Food and Drug Administration |
| GLS | Geometric least squares |
| IQR | Interquartile range |
| IRD | Inherited retinal disease |
| IVI | Impact of Vision Impairment |
| logMAR | Logarithm of the minimum angle of resolution |
| mFAS | Modified full analysis set |
| mMP | Mesopic microperimetry |
| MMRM | Mixed Model for Repeated Measures |
| NDA | New Drug Application |
| NEI VFQ | National Eye Institute Visual Function Questionnaire |
| p.o. | Orally |
| qAF | Quantitative autofluorescence |
| QD | Once daily |
| QDAF | Questionably decreased autofluorescence |
| QoL | Quality of life |
| RBP4 | Retinol-binding protein 4 |
| REC | Research Ethics Committee |
| SD | Stargardt disease |
| STGD | Stargardt disease |
| STGD1 | Stargardt disease type 1 |
| TEAE | Treatment-emergent adverse event |
| USD | United States dollar |

## Related pages
- [Tinlarebant (LBS-008): Stargardt disease type 1](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1.md)
- [Tinlarebant (LBS-008): Stargardt disease type 1](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/executive-summary.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Product information and disease description](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/product-information-and-disease-description.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Clinical evidence](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/clinical-evidence.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Economic information and modeling report](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/economics) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/economics.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: References](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/references) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/references.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: prevalence by geography](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/prevalence) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/prevalence.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/cost-effectiveness-analyses.md)
